LIAISON QuantiFERON - TB Gold Plus, LIAISON Control QuantiFERON - TB Gold Plus and LIAISON QuantiFERON Software
DiaSorin, Inc. · Decision date Nov 26, 2019
What did the FDA approve?
FDA approved DiaSorin's LIAISON QuantiFERON-TB Gold Plus assay, its control, and optional software. The assay detects interferon-gamma in lithium heparin plasma by chemiluminescence immunoassay on the LIAISON XL Analyzer, using QIAGEN QuantiFERON-TB Gold Plus Blood Collection Tubes containing ESAT-6 and CFP-10 peptide cocktails to stimulate cells in heparinized whole blood. It is a qualitative indirect test for Mycobacterium tuberculosis infection, including disease, intended for use with risk assessment, radiography, and other evaluations.
The LIAISON Control QuantiFERON-TB Gold Plus is an assayed quality control for monitoring assay performance, with performance characteristics established only on the LIAISON XL Analyzer. The LIAISON QuantiFERON Software is optional and reports positive, negative, or indeterminate results by combining data from the four blood collection tubes. The approval statement describes intended use and reported purpose; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
Approval for the LIAISON QuantiFERON-TB Gold Plus assay, the LIAISON Control QuantiERON-TB Gold Plus, and the LIAISON QuantiFERON Software.The LIAISON QuantiFERON-TB Gold Plus assay is an in vitro diagnostic test intended for the detection of interferon-y (IFN-y) in human lithium heparin plasma by chemiluminescence immunoassay (CLIA) using the LIAISON XL Analyzer. QIAGEN QuantiFERON-TB Gold Plus Blood Collection Tubes, containing a peptide cocktail simulating ESAT-6, and CFP-10 proteins, are used in conjunction with the LIAISON QuantiFERON-TB Gold Plus assay to stimulate cells in heparinized whole blood. Detection of IFN-y is used to identify in vitro responses to these peptide antigens that are associated with Mycobacterium tuberculosis infection.The assay is a qualitative indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations to assist the clinician in making individual patient management decisions. The LIAISON QuantiFERON-TB Gold Plus assay must be performed using the LIAISON XL Analyzer.The LIAISON Control QuantiFERON-TB Gold Plus is intended for use as assayed quality control samples to monitor the performance of the LIAISON QuantiFERON-TB Gold Plus assay. The performance characteristics of LIAISON Control QuantiFERON-TB Gold Plus have not been established for any other assays or instrument platforms other than the LIAISON XL Analyzer.The LIAISON QuantiFERON Software (LQS) is optional software intended to analyze the data generated by the LIAISON QuantiFERON-TB Gold Plus assay on the LIAISON XL Analyzer. LQS reports assay results as positive, negative, or indeterminate by an algorithm that combines the individual results associated with the four QIAGEN QuantiFERON-TB Gold Plus Blood Collection Tubes into a final result.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Microbiology
- Decision date
- Nov 26, 2019
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P180047
- Regulatory pathway
- Premarket approval application
- Applicant
- DiaSorin, Inc.
- Product code
- NCD
- Decision code
- APPR
- Decision date
- Nov 26, 2019
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.
- Applicant
- DiaSorin, Inc.
- Product code
- NCD
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P180047 received
Application receipt date recorded by FDA.
P180047 · FDA decision
APPR
P180047/S046 · Related supplement
LIAISON QuantiFERON-TB Gold Plus II.
Timeline entries are records held by MedtechLedger for P180047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180047
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIAISON QuantiFERON-TB Gold Plus II.P180047/S046 | DiaSorin, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code NCD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QuantiFERON-TB Gold Plus TestP010033/S053 | Qiagen | PMA supplement | Oct 14, 2026 | FDA |
| Qiagen | PMA approval | Nov 28, 2001 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
DiaSorin, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1951 Northwestern Ave., Stillwater, MN, 55082
Sources and methodology
- Original FDA record: P180047
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
